Medical News

January 15 2004–The therapeutic vaccine market is in its infancy with no significant products launched across the seven major markets. Despite the unproven nature of the sector in terms of market potential, it is commanding considerable interest across the biotechnology industry. Indeed. Datamonitor has identified 65 companies developing therapeutic vaccines, with 167 products in development.

Scope

Benchmarking of the current and future vaccine market, by technology and therapeutic focus, in terms of number of projects and dollar value

Assesses the steps that emerging players are taking to increase innovation in their businesses, integrate supply chain and improve strategic position

Analysis of market trends and future opportunities for both biotech and pharmaceutical players, with supporting case studies

Full profiles of 6 leading therapeutic vaccine players, encompassing company strategy, alliance networking, portfolio and pipeline analysis

Report Highlights

The therapeutic vaccine market will not receive significant attention from the wider pharmaceutical industry until a product is launched and achieves significant uptake across the seven major markets. The most likely drug to achieve this is Dendreon?s Provenge, although Dendreon must recruit a marketing partner before this can be achieved.

For companies that are totally focused on therapeutic vaccines, the only way to survive is through a strong network of partners. The unproven technology behind therapeutic vaccines, combined with the number of setbacks that the leading products have encountered, is inhibiting therapeutic vaccine companies? abilities to form partnerships.

Oncology dominates therapeutic vaccines both in terms of commercial potential and pipeline development. Colorectal, melanoma and prostate cancer have the most therapeutic vaccines in development. However, the therapeutic vaccine early stage pipeline is split across more therapy areas, with an increased focus on infectious disease, CNS and HIV.

This report is designed to:

Benchmark your position within the vaccine market and identify the optimum strategy for future success

Forecast how advances in science and changes in the commercial environment will offer new opportunities to benefit from therapeutic vaccines

Identify key pipeline products for in-licensing opportunities as well as areas of unmet need

For a complete index of this report click on http://www.researchandmarkets.com/reports/42628

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

January 15 2004–The therapeutic vaccine market is in its infancy with no significant products launched across the seven major markets. Despite the unproven nature of the sector in terms of market potential, it is commanding considerable interest across the biotechnology industry. Indeed. Datamonitor has identified 65 companies developing therapeutic vaccines, with 167 products in development.

Scope

Benchmarking of the current and future vaccine market, by technology and therapeutic focus, in terms of number of projects and dollar value

Assesses the steps that emerging players are taking to increase innovation in their businesses, integrate supply chain and improve strategic position

Analysis of market trends and future opportunities for both biotech and pharmaceutical players, with supporting case studies

Full profiles of 6 leading therapeutic vaccine players, encompassing company strategy, alliance networking, portfolio and pipeline analysis

Report Highlights

The therapeutic vaccine market will not receive significant attention from the wider pharmaceutical industry until a product is launched and achieves significant uptake across the seven major markets. The most likely drug to achieve this is Dendreon?s Provenge, although Dendreon must recruit a marketing partner before this can be achieved.

For companies that are totally focused on therapeutic vaccines, the only way to survive is through a strong network of partners. The unproven technology behind therapeutic vaccines, combined with the number of setbacks that the leading products have encountered, is inhibiting therapeutic vaccine companies? abilities to form partnerships.

Oncology dominates therapeutic vaccines both in terms of commercial potential and pipeline development. Colorectal, melanoma and prostate cancer have the most therapeutic vaccines in development. However, the therapeutic vaccine early stage pipeline is split across more therapy areas, with an increased focus on infectious disease, CNS and HIV.

This report is designed to:

Benchmark your position within the vaccine market and identify the optimum strategy for future success

Forecast how advances in science and changes in the commercial environment will offer new opportunities to benefit from therapeutic vaccines

Identify key pipeline products for in-licensing opportunities as well as areas of unmet need

For a complete index of this report click on http://www.researchandmarkets.com/reports/42628

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com